Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 7, Issue 2, 2026

Efficacy of Nano Spherical-crystallized S-equol on Ovarian Physiological Age, Menopausal Symptoms, Menstrual Regularity, and Dermal Microstructure: A 12-Week Pilot Study

Download as PDF

DOI: 10.23977/medsc.2026.070216 | Downloads: 3 | Views: 73

Author(s)

Naizhuang Jake Wang 1, Ella Wang 1, Jingjing Dai 1

Affiliation(s)

1 Eternal Grace R&D Center, GPO Lief Pte. Ltd., Singapore

Corresponding Author

Naizhuang Jake Wang

ABSTRACT

This 12-week pilot study evaluated the effects of Nano Spherical-crystallized S-equol in 12 perimenopausal women aged 45–55 years on ovarian physiological age-related endocrine biomarkers, menopausal symptoms, menstrual regularity, and skin microstructure. Daily supplementation with 5 mg of Nano Spherical-crystallized S-equol significantly increased circulating S-equol levels, confirming effective systemic exposure. Serum inhibin B levels increased by 14.4%, suggesting improved ovarian endocrine function and an endocrine profile corresponding to an ovarian physiological age approximately 5.6 years younger than chronological age. In addition, total menopausal symptom scores decreased by 63.8%, while premenstrual and menstrual symptom burden was reduced by 52.4%. The proportion of participants with regular menstrual cycles increased from 25.0% to 66.7%. Improvements were also observed in skin hydration, elasticity, wrinkle depth, transepidermal water loss, and skin roughness. These findings suggest that Nano Spherical-crystallized S-equol may support ovarian endocrine health, alleviate menopausal discomfort, improve menstrual cycle stability, and promote healthier skin aging in perimenopausal women. However, larger randomized, double-blind, placebo-controlled studies are needed to confirm these preliminary results.

KEYWORDS

Nano Spherical-crystallized S-equol, ERβ, Inhibin B, Ovarian Aging, Menopause, Menstrual Regularity, Skin Microstructure

CITE THIS PAPER

Naizhuang Jake Wang, Ella Wang, Jingjing Dai. Efficacy of Nano Spherical-crystallized S-equol on Ovarian Physiological Age, Menopausal Symptoms, Menstrual Regularity, and Dermal Microstructure: A 12-Week Pilot Study. MEDS Clinical Medicine (2026). Vol. 7, No.2, 128-136. DOI: http://dx.doi.org/10.23977/medsc.2026.070216.

REFERENCES

[1] Burger HG, Hale GE, Robertson DM, et al. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women’s Midlife Health Project. Human Reproduction Update. 2007;13(6): 559–565.
[2] Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-Mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. The Journal of Clinical Endocrinology & Metabolism. 2008;93(9): 3478–3483.
[3] Rowland I, Faughnan M, Hoey L, et al. Bioavailability of phyto-oestrogens. British Journal of Nutrition. 2003;89: S45–S58.
[4] Jackson RL, Greiwe JS, Schwen RJ. Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist. Nutrition Reviews. 2011;69(8): 432–448.
[5] Burger HG. The menopausal transition: endocrinology. Journal of Sexual Medicine. 2008;5(10): 2266–2273.
[6] Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol — a clue to the effectiveness of soy and its isoflavones. The Journal of Nutrition. 2002;132(12): 3577–3584.
[7] Setchell KDR, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. The American Journal of Clinical Nutrition. 2005;81(5): 1072–1079.
[8] Muthyala RS, Ju YH, Sheng S, et al. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and transcriptional activity involving estrogen receptors alpha and beta. Bioorganic & Medicinal Chemistry. 2004;12(6): 1559–1567.
[9] Ishiwata N, Melby MK, Mizuno S, et al. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause. 2009;16(1): 141–148.
[10] Jenks BH, Iwashita S, Nakagawa Y, et al. A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. Journal of Women’s Health. 2012;21(6): 674–682.
[11] Oyama A, Ueno T, Uchiyama S, et al. The effects of natural S-equol supplementation on skin aging in postmenopausal women: a pilot randomized placebo-controlled trial. Menopause. 2012;19(2): 202–210.
[12] Chatterjee A, Gupta MM, Srivastava B. Spherical crystallization: a technique use to reform solubility and flow property of active pharmaceutical ingredients. International Journal of Pharmaceutical Investigation. 2017;7(1): 4–9.
[13] Maghsoodi M, Yari Z, Sadeghpoor F. Agglomeration of celecoxib by quasi emulsion solvent diffusion method: effect of stabilizer. Advanced Pharmaceutical Bulletin. 2016;6(1): 121–130.
[14] Pitt K, Peña R, Tew JD, et al. Particle design via spherical agglomeration: a critical review of controlling parameters, rate processes and modelling. Powder Technology. 2018;326: 327–343.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 11795
Visits: 999858

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.